A61K31/35

Use of <i>Pulsatilla chinensis </i>extract in the preparation of drugs for treatment of viral and/or bacterial diseases

Disclosed are uses of a Pulsatilla saponin compound B4 or a pharmaceutically acceptable salt thereof in preparing a drug for treating viral and/or bacterial diseases. The Pulsatilla saponin compound B4 disclosed by the invention shows a strong biological activity, and efficiently treats endometritis, footrot, feline parvovirus, canine parvovirus, canine distemper, canine kidney failure, and canine acute nephritis. ##STR00001##

FORMULATIONS OF HISTONE DEACETYLASE INHIBITOR AND USES THEREOF

Dosing regimens, methods of treatment, controlled release formulations, and combination therapies that include an HDAC inhibitor, or a pharmaceutically acceptable salt thereof, are described.

FORMULATIONS OF HISTONE DEACETYLASE INHIBITOR AND USES THEREOF

Dosing regimens, methods of treatment, controlled release formulations, and combination therapies that include an HDAC inhibitor, or a pharmaceutically acceptable salt thereof, are described.

METHODS AND COMPOSITIONS FOR ATTENUATING ALLERGENICITY IN PROTEIN PRODUCTS
20170333386 · 2017-11-23 ·

The invention relates to a low sugar or sugar free concentrated polyphenolic extract comprising at least about 30% polyphenols (w/w) and a protein-polyphenol aggregate matrix comprising at least about 15% polyphenols (w/w). The invention further relates to methods of producing a low sugar or sugar free concentrated polyphenolic extract comprising (a) extracting a low sugar or sugar free plant tissue with an aqueous solvent to produce an extract having an aqueous portion and a solids portion; (b) filtering the extract to separate the aqueous portion from the solids portion; and (c) reducing the volume of the separated aqueous portion, and methods of producing a protein-polyphenol aggregate matrix comprising about 1% to about 40% polyphenols (w/w) using the low sugar or sugar free concentrated polyphenolic extract of the invention.

METHODS AND COMPOSITIONS FOR ATTENUATING ALLERGENICITY IN PROTEIN PRODUCTS
20170333386 · 2017-11-23 ·

The invention relates to a low sugar or sugar free concentrated polyphenolic extract comprising at least about 30% polyphenols (w/w) and a protein-polyphenol aggregate matrix comprising at least about 15% polyphenols (w/w). The invention further relates to methods of producing a low sugar or sugar free concentrated polyphenolic extract comprising (a) extracting a low sugar or sugar free plant tissue with an aqueous solvent to produce an extract having an aqueous portion and a solids portion; (b) filtering the extract to separate the aqueous portion from the solids portion; and (c) reducing the volume of the separated aqueous portion, and methods of producing a protein-polyphenol aggregate matrix comprising about 1% to about 40% polyphenols (w/w) using the low sugar or sugar free concentrated polyphenolic extract of the invention.

Methods of Treating Hyperalgesia
20170333385 · 2017-11-23 ·

This application describes compounds and methods that can be used to treat, reverse, or avoid hyperalgesia.

Methods of Treating Hyperalgesia
20170333385 · 2017-11-23 ·

This application describes compounds and methods that can be used to treat, reverse, or avoid hyperalgesia.

Methods and compositions for treating cancer

This disclosure provides compositions and method useful for treating cell proliferative disorders including cancer. The disclosure provides cannabidiol derivatives and compositions thereof either alone or in combination with THC or a derivative thereof.

Methods and compositions for treating cancer

This disclosure provides compositions and method useful for treating cell proliferative disorders including cancer. The disclosure provides cannabidiol derivatives and compositions thereof either alone or in combination with THC or a derivative thereof.

METHODS OF TREATING SUBSTANCE ABUSE
20220347124 · 2022-11-03 ·

The disclosure provides a method of treating a substance use disorder in a subject, comprising administering to the subject a therapeutically effective amount of a composition comprising R(−)-ketamine or a pharmaceutically acceptable salt thereof, wherein the composition is substantially free of S(+)-ketamine or a pharmaceutically acceptable salt thereof.